Matrixyl

01 · What it is

Matrixyl is a piece of collagen used to tell skin to make more collagen.

KTTKS is a matrikine — a peptide fragment that originates from the proteolytic hydrolysis of collagen itself. In cell culture it stimulates extracellular matrix production and the expression of types I and III collagen. A more stable form is pal-KTTKS, known commercially as Matrixyl or palmitoyl pentapeptide-4 ².

The logic is genuinely elegant. Collagen breakdown products are a signal the body already uses to report tissue damage. Supplying that fragment is an attempt to trigger the repair response without the damage. The palmitoyl tail is added for stability and for lipid solubility.

What the evidence actually consists of. In vitro collagen expression in fibroblasts ^2,8, a comparison of patch versus cream delivery in an in vivo wound-healing model ³, self-assembly and collagen-production studies of the lipopeptide ¹⁰, and hybrid constructs coupling the pentapeptide to ionic liquids to add antibacterial activity ⁴. This guide located no randomised controlled trial of Matrixyl on human skin.

And the same problem as everything else in this family. Cosmetically active compounds have difficulty reaching the deeper layers of the skin, and this significantly reduces their efficacy ⁷. Fibroblasts sit in the dermis. A cell-culture experiment delivers the peptide directly to them; a cream has to get it past the stratum corneum first.

One study made the delivery question explicit by comparing a Matrixyl patch against a Matrixyl cream, and reported that the compound’s contribution to collagen formation during wound healing depends on its mode of delivery ³.

02 · Evidence at a glance

Evidence grade

Preclinical — no randomised human trial located

What it is

Palmitoyl pentapeptide-4; pal-KTTKS or C16-KTTKS ^2,10

Origin of the sequence

A matrikine from proteolytic hydrolysis of collagen ²

Proposed mechanism

Stimulation of extracellular matrix production and type I and III collagen expression, demonstrated in vitro ²

Why palmitoylated

Greater stability than free KTTKS ²

Delivery dependence

Contribution to collagen formation depends on mode of delivery — patch versus cream ³

Class-level permeation problem

Cosmetically active compounds struggle to reach deeper skin layers, significantly reducing efficacy ⁷

Human clinical trials located

None

Where collagen stimulation is measured

Fibroblast culture ^2,8 and lipopeptide preparations ¹⁰

Cytotoxicity

Assessed for a novel-analogue series ²; used as a comparator in a marine-peptide study reporting a toxicity difference ¹

Analogues under development

Arginine-substituted C16-RTTRS ¹⁰; ionic-liquid hybrids ⁴; novel KTTKS series ²

Regulatory category

A cosmetic ingredient, not a drug

03 · Mechanism of action

A damage signal, supplied without the damage

KTTKS is a fragment released when collagen is broken down ². Matrikines of this kind function as feedback signals: their presence indicates that matrix has been degraded, and the fibroblast response is to synthesise replacement. Applying the fragment exogenously is an attempt to invoke that response directly.

This is one of the more intellectually satisfying mechanisms in the project, and it is worth separating the elegance of the idea from the strength of the evidence for the product.

What has been demonstrated, and where

The peptide stimulates extracellular matrix production and types I and III collagen expression in vitro ². Studies of the lipopeptide C16-KTTKS have examined self-assembly in aqueous solution, cytocompatibility and collagen production, alongside an arginine-substituted variant C16-RTTRS ¹⁰. Cosmetic peptides including palmitoyl pentapeptide-4 have been assessed for effects on dermal fibroblast viability and extracellular matrix gene expression, in combination with injectable platelet-rich fibrin ⁸.

Every one of these puts the peptide and the fibroblast in the same dish. None of them tests whether a topically applied product achieves that.

The palmitoyl group does two jobs and creates a third question

Palmitoylation makes the peptide more stable ² and more lipophilic, which aids passage through the stratum corneum. But C16-KTTKS self-assembles in aqueous solution ¹⁰ — the same lipid tail that carries it into lipid membranes also drives the molecules to aggregate with each other.

A compound whose behaviour depends on its own concentration and formulation is one where the relationship between what is in the bottle and what reaches a cell is not straightforward. The 2026 work characterising that nanostructure is the most mechanistically careful paper in this file ¹⁰.

Where the field has gone instead

Rather than clinical trials, recent work builds derivatives. Imidazolium-based ionic liquids have been coupled to pentapeptide-4 to produce leads with both antimicrobial and collagenesis-inducing activity ⁴. A series of novel KTTKS analogues has been assessed for cytotoxicity and proteolytic activity ².

The pattern this project has now seen repeatedly: when a compound’s plain form is hard to deliver or hard to demonstrate, the literature turns into chemistry.

04 · Key research findings

Comparator use, 2019. A study of an N-terminally acetylated, C-terminally amidated Spirulina platensis-derived hexapeptide used Matrixyl as its positive control, reporting a cytotoxicity comparison in HaCaT keratinocytes alongside effects on malondialdehyde, superoxide dismutase, catalase, glutathione peroxidase, and MMP-1 and MMP-3 expression ¹.

The abstract’s paired percentages are not interpretable without the full text, so this guide reports the comparison as made rather than stating its direction. That it was made at all is the point: a marine peptide was benchmarked against Matrixyl on toxicity, not only on efficacy.

The analogue series, 2019. A study of novel KTTKS analogues examining cytotoxicity and proteolytic activity, and setting out the underlying biology — KTTKS as a collagen-derived matrikine stimulating extracellular matrix production and type I and III collagen expression in vitro, with pal-KTTKS as the more stable commercial form ².

The clearest single statement in this file of what Matrixyl is and what it has been shown to do.

Patch versus cream, 2022. A comparative in vivo investigation of Matrixyl’s effect on wound healing, contrasting a patch formulation with a cream, and reporting that the contribution to collagen formation during wound healing depends on the mode of delivery ³.

The most directly useful study for a reader evaluating a product, and its finding is that the vehicle matters.

Hybrid constructs, 2022. Imidazolium-based ionic liquids coupled to pentapeptide-4, building on earlier dual-action antibacterial and collagenesis-inducing constructs based on the same sequence ⁴.

Liposomal delivery in the class, 2023. Liposomes developed as carriers for the copper-binding anti-ageing and wound-healing peptide GHK-Cu, using anionic and cationic hydrogenated lecithin formulations ⁵.

Included because it is the same problem being solved for a neighbouring compound, and because the solution is a delivery vehicle rather than a better peptide.

Clinical context, 2024. A review of cosmeceuticals in photoaging covering botanicals, peptides and hydroquinone in cosmetic medicine ⁶.

The permeation question, 2025. A review asking whether the field is currently able to measure skin permeation of modern anti-ageing peptides encapsulated in liposomes, and stating that cosmetically active compounds of both lipophilic and hydrophilic origin have difficulty reaching the deeper layers of the skin, significantly reducing their efficacy ⁷.

Fibroblast work, 2025. Synergistic effects of injectable platelet-rich fibrin and bioactive peptides including palmitoyl pentapeptide-4 on dermal fibroblast viability and extracellular matrix gene expression, in vitro ⁸.

Note the route in that study’s framing: injectable platelet-rich fibrin. The peptide is being assessed alongside a procedure that bypasses the skin barrier entirely.

Safety framework, 2026. A framework for the safety evaluation of peptides in cosmetics, tested against a panel that includes palmitoyl pentapeptide-4 alongside alpha-amanitin, conotoxin and bradykinin ⁹.

Nanostructure, 2026. Investigation of self-assembly in aqueous solution, cytocompatibility and collagen production for C16-KTTKS and the arginine-substituted variant C16-RTTRS, noting that C16-KTTKS is known commercially as Matrixyl and used in cosmetic formulations ¹⁰.

05 · Evidence overview

06 · Safety profile

Human data. No clinical trial was located. Matrixyl is a cosmetic ingredient, and the evidence requirements it has met are cosmetic-safety requirements rather than clinical ones.

Laboratory data. Cytocompatibility has been examined for the lipopeptide and its variant ¹⁰, cytotoxicity and proteolytic stability for a series of analogues ², and a cytotoxicity comparison was drawn against a marine peptide in keratinocytes ¹. A 2026 framework paper sets out a computational approach to evaluating peptide safety in cosmetics ⁹.

What is genuinely unknown. Systemic absorption. Whether the peptide reaches dermal fibroblasts in usable quantity from a topical product — which is simultaneously the efficacy question and the reason systemic safety concerns are probably small. Long-term repeated use. Behaviour on compromised skin, where barrier function differs.

Two points specific to this compound. Self-assembly means the applied species may not be the characterised species ¹⁰: aggregation state depends on concentration and vehicle, and no cited work establishes what state a commercial formulation delivers. And stimulating matrix synthesis is not intrinsically benign — the mechanism is a fibroblast activation signal, and no located source addresses what sustained stimulation does over years, or in skin with existing fibrotic or proliferative pathology.

Nothing is published on the identity or purity of any Matrixyl-labelled product.

07 · US regulatory status

Current as of 7 September 2026. Palmitoyl pentapeptide-4 is a cosmetic ingredient. It is not an approved drug and not a controlled substance. Cosmetics are not required to demonstrate efficacy before sale, which is the regulatory reason this guide’s evidence section looks as it does.

This guide has not consulted cosmetic regulatory records, ingredient listings or safety assessments in any jurisdiction, and makes no statement about permitted concentrations or restrictions.

Under the World Anti-Doping Code, palmitoyl pentapeptide-4 does not appear as a named prohibited substance in the classes reviewed here.

08 · Limitations of the evidence

1. No randomised controlled trial on human skin was located, for a product sold for over two decades.

1. The collagen evidence is in vitro ^2,8,10, where the peptide is applied directly to fibroblasts. That design removes the single step — crossing the skin barrier — that determines whether a topical product works.

1. The one delivery comparison found that delivery matters ³. A result obtained with a patch does not transfer to a cream, and neither transfers to an arbitrary commercial serum.

1. The class literature states that permeation is both limiting and hard to measure ⁷, so target engagement cannot be verified from what exists.

1. Self-assembly complicates the identity question ¹⁰. Concentration and vehicle determine aggregation state, and no source characterises that for a marketed product.

1. Analogue studies are not evidence for the parent compound. Ionic-liquid hybrids ⁴ and novel KTTKS series ² are different molecules.

1. One comparator result is reported here without direction ¹, because the abstract’s paired percentages cannot be assigned confidently without the full text. That is logged rather than guessed.

1. The regulatory category never required efficacy evidence, so its absence reflects how these products reach market rather than a specific failure.

1. This guide has read abstracts, not full texts, for every source cited.

1. Nothing is known about specific products. No independent analysis of any Matrixyl-labelled product was located.

09 · References

1. Zeng Q, Jiang J, Wang J, Zhou Q, Zhang X. N-terminal acetylation and C-terminal amidation of Spirulina platensis-derived hexapeptide: anti-photoaging activity and proteomic analysis. Mar Drugs. 2019 Sep 4;17(9):520.

   PMID 31487895 ↗

2. Tałałaj U, Uścinowicz P, Bruzgo I, Surażyński A, Zaręba I, Markowska A. The effects of a novel series of KTTKS analogues on cytotoxicity and proteolytic activity. Molecules. 2019 Oct 15;24(20):3698.

   PMID 31618846 ↗

3. Kachooeian M, Mousivand Z, Sharifikolouei E, Shirangi M, Firoozpour L, Raoufi M, Sharifzadeh M. Matrixyl patch vs Matrixyl cream: a comparative in vivo investigation of Matrixyl (MTI) effect on wound healing. ACS Omega. 2022 Jul 11;7(28):24695–24704.

   PMID 35874243 ↗

4. Gomes A, Bessa LJ, Fernandes I, Aguiar L, Ferraz R, Monteiro C, Martins MCL, Mateus N, Gameiro P, Teixeira C, Gomes P. Boosting cosmeceutical peptides: coupling imidazolium-based ionic liquids to pentapeptide-4 originates new leads with antimicrobial and collagenesis-inducing activities. Microbiol Spectr. 2022 Aug 31;10(4):e0229121.

   PMID 35950860 ↗

5. Dymek M, Olechowska K, Hąc-Wydro K, Sikora E. Liposomes as carriers of GHK-Cu tripeptide for cosmetic application. Pharmaceutics. 2023 Oct 18;15(10):2485.

   PMID 37896245 ↗

6. Chan LKW, Lee KWA, Lee CH, Lam KWP, Lee KFV, Wu R, Wan J, Shivananjappa S, Sky WTH, Choi H, Yi KH. Cosmeceuticals in photoaging: a review. Skin Res Technol. 2024 Sep;30(9):e13730.

   PMID 39233460 ↗

7. Ogórek K, Nowak K, Wadych E, Ruzik L, Timerbaev AR, Matczuk M. Are we ready to measure skin permeation of modern antiaging GHK-Cu tripeptide encapsulated in liposomes? Molecules. 2025 Jan 1;30(1):136. Review.

   PMID 39795193 ↗

8. Paccola AGL, Santos TMCD, Minelo MC, Garbieri TF, Sanches MLR, Dionísio TJ, Oliveira RC, Santos CF, Buzalaf MAR. Synergistic effects of injectable platelet-rich fibrin and bioactive peptides on dermal fibroblast viability and extracellular matrix gene expression: an in vitro study. Molecules. 2025 Aug 19;30(16):3415.

   PMID 40871567 ↗

9. Bjerke DL, Li J, Gao Y, Hu P, Lintner K, Hakozaki T. A framework for the safety evaluation of peptides in cosmetics. Curr Res Toxicol. 2026 Mar 20;10:100291.

   PMID 41953401 ↗

10. de Mello LR, Castelletto V, Seitsonen J, Hamley IW. Nanostructure and collagen-stimulating activity of cationic pentapeptide lipopeptides. J Pept Sci. 2026 Aug;32(8):e70111.

    PMID 42317129 ↗